Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Ruland J. Inflammasome: putting the pieces together. Cell. 2014 Mar 13;156(6):1127–1129.
   PubMed Web of Science ®Google Scholar
• Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010 Jun;10(6):387–402.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. The osteoclast and its unique cytoskeleton. Ann N Y Acad Sci. 2011 Dec;1240:14–17.
   PubMed Web of Science ®Google Scholar
• Lowell CA. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol. 2011 Mar 1;3(3):a002352.
   PubMed Web of Science ®Google Scholar
• Zou W, Teitelbaum SL. Integrins, growth factors, and the osteoclast cytoskeleton. Ann N Y Acad Sci. 2010 Mar;1192:27–31.
   PubMed Web of Science ®Google Scholar
• Jakus Z, Fodor S, Abram CL, et al. Immunoreceptor-like signaling by beta 2 and beta 3 integrins. Trends Cell Biol. 2007 Oct;17(10):493–501.
   PubMed Web of Science ®Google Scholar
• Kumaran S, Grucza RA, Waksman G. The tandem Src homology 2 domain of the Syk kinase: a molecular device that adapts to interphosphotyrosine distances. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14828–14833.
   PubMed Web of Science ®Google Scholar
• Sada K, Takano T, Yanagi S, et al. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001 Aug;130(2):177–186.
   PubMed Web of Science ®Google Scholar
• Latour S, Zhang J, Siraganian RP, et al. A unique insert in the linker domain of Syk is necessary for its function in immunoreceptor signalling. Embo J. 1998 May 1;17(9):2584–2595.
   PubMed Web of Science ®Google Scholar
• Geahlen RL. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci. 2014 Aug;35(8):414–422.
   PubMed Web of Science ®Google Scholar
• Bruserud O, Gjertsen BT, Ulvestad E. Expression of Fc(epsilon)-receptors by human acute myelogenous leukemia (AML) blasts: studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML blast characteristics. Leuk Res. 2002 May;26(5):515–521.
   PubMed Web of Science ®Google Scholar
• Bassoe CF, Halstensen A, Bruserud O. Functional differentiation of acute myeloid leukaemia blast cells. Apmis. 1999 Nov;107(11):1023–1033.
   PubMed Web of Science ®Google Scholar
• Dunphy CH, Tang W. The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med. 2007 May;131(5):748–754.
   PubMed Web of Science ®Google Scholar
• Sergeeva A, Ono Y, Rios R, et al. High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease. Leukemia. 2008 Apr;22(4):783–790.
   PubMed Web of Science ®Google Scholar
• Larson RA, Lukin CL, Daly KM, et al. Circulating immune complexes correlate with remission duration in acute myeloid leukemia. Leukemia. 1991 Feb;5(2):131–137.
   PubMed Web of Science ®Google Scholar
• Carpentier NA, Fiere DM, Schuh D, et al. Circulating immune complexes and the prognosis of acute myeloid leukemia. N Engl J Med. 1982 Nov 4;307(19):1174–1180.
   PubMed Web of Science ®Google Scholar
• Tohyama Y, Yamamura H. Complement-mediated phagocytosis–the role of Syk. IUBMB Life. 2006 May–Jun;58(5–6):304–308.
   PubMed Web of Science ®Google Scholar
• Laverdiere I, Boileau M, Herold T, et al. Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia. Exp Hematol. 2016 Nov;44(11):1039–43 e10.
   PubMed Web of Science ®Google Scholar
• Abdelbaset-Ismail A, Borkowska-Rzeszotek S, Kubis E, et al. Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1. Leukemia. 2017 Feb;31(2):446–458.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Andersson Tvedt TH, Bruserud O. The complexity of targeting PI3K-Akt-mTOR signalling in human acute myeloid leukaemia: the importance of leukemic cell heterogeneity, neighbouring mesenchymal stem cells and immunocompetent cells. Molecules. 2016 Nov 11;21(11):1512.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Nepstad I, Bruserud O. Mesenchymal stem cells support survival and proliferation of primary human acute myeloid leukemia cells through heterogeneous molecular mechanisms. Front Immunol. 2017;8:106.
   PubMed Web of Science ®Google Scholar
• Kim JA, Shim JS, Lee GY, et al. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res. 2015 Jun 1;75(11):2222–2231.
   PubMed Web of Science ®Google Scholar
• Ito S, Barrett AJ, Dutra A, et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res. 2015 Jan;14(1):95–104.
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002 Sep 20;110(6):673–687.
   PubMed Web of Science ®Google Scholar
• Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci. 2006 Oct 1;119(Pt 19):3901–3903.
   PubMed Web of Science ®Google Scholar
• Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol. 2005;21:381–410.
   PubMed Web of Science ®Google Scholar
• Springer TA, Wang JH. The three-dimensional structure of integrins and their ligands, and conformational regulation of cell adhesion. Adv Protein Chem. 2004;68:29–63.
   PubMedGoogle Scholar
• Gullberg D. What has been. Adv Exp Med Biol. 2014;819:v–xii.
   PubMedGoogle Scholar
• Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010 Jan;339(1):269–280.
   PubMed Web of Science ®Google Scholar
• Winograd-Katz SE, Fassler R, Geiger B, et al. The integrin adhesome: from genes and proteins to human disease. Nat Rev Mol Cell Biol. 2014 Apr;15(4):273–288.
   PubMed Web of Science ®Google Scholar
• Becker PS, Kopecky KJ, Wilks AN, et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood. 2009 Jan 22;113(4):866–874.
   PubMed Web of Science ®Google Scholar
• Walter RB, Alonzo TA, Gerbing RB, et al. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children’s oncology group. J Clin Oncol. 2010 Jun 10;28(17):2831–2838.
   PubMed Web of Science ®Google Scholar
• Tavernier-Tardy E, Cornillon J, Campos L, et al. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res. 2009 Jun;33(6):764–768.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003 9;Sep(9):1158–1165.
   Google Scholar
• Bae MH, Oh SH, Park CJ, et al. VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia. Ann Hematol. 2015 Oct;94(10):1631–1638.
   PubMed Web of Science ®Google Scholar
• Lin TH, Rosales C, Mondal K, et al. Integrin-mediated tyrosine phosphorylation and cytokine message induction in monocytic cells. A possible signaling role for the Syk tyrosine kinase. J Biol Chem. 1995 Jul 7;270(27):16189–16197.
   PubMed Web of Science ®Google Scholar
• Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 2007 Mar;92(3):332–341.
   PubMed Web of Science ®Google Scholar
• Krisenko MO, Geahlen RL. Calling in SYK: SYK’s dual role as a tumor promoter and tumor suppressor in cancer. Biochim Biophys Acta. 2015 Jan;1853(1):254–263.
   PubMed Web of Science ®Google Scholar
• Oellerich T, Oellerich MF, Engelke M, et al. Beta2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. Blood. 2013 May 9;121(19):3889–3899, S1–S66.
   PubMed Web of Science ®Google Scholar
• Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 6;16(4):281–294.
   PubMed Web of Science ®Google Scholar
• Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood. 2008 May 1;111(9):4797–4808.
   PubMed Web of Science ®Google Scholar
• Tsubokawa M, Tohyama Y, Tohyama K, et al. Interleukin-3 activates Syk in a human myeloblastic leukemia cell line, AML193. Eur J Biochem. 1997 Nov 1;249(3):792–796.
   PubMedGoogle Scholar
• Mohr S, Doebele C, Comoglio F, et al. Hoxa9 and Meis1 cooperatively induce addiction to syk signaling by suppressing miR-146a in acute myeloid leukemia. Cancer Cell. 2017 Apr 10;31(4):549–62 e11.
   PubMed Web of Science ®Google Scholar
• Argiropoulos B, Palmqvist L, Yung E, et al. Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. Exp Hematol. 2008 Jul;36(7):845–859.
   PubMed Web of Science ®Google Scholar
• Gibbs KD Jr, Jager A, Crespo O, et al. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell. 2012 Feb 3;10(2):210–217.
   PubMed Web of Science ®Google Scholar
• Shah CA, Bei L, Wang H, et al. Cooperation between AlphavBeta3 integrin and the fibroblast growth factor receptor enhances proliferation of Hox-overexpressing acute myeloid leukemia cells. Oncotarget. 2016 Aug 23;7(34):54782–54794.
   PubMedGoogle Scholar
• Roche J, Zeng C, Baron A, et al. Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. Leukemia. 2004 Jun;18(6):1059–1063.
   PubMed Web of Science ®Google Scholar
• Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007 Oct 15;26(47):6766–6776.
   PubMed Web of Science ®Google Scholar
• Yi H, Zeng D, Shen Z, et al. Integrin alphavbeta3 enhances beta-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. Oncotarget. 2016 Jun 28;7(26):40387–40397.
   PubMed Web of Science ®Google Scholar
• Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010 Mar 26;327(5973):1650–1653.
   PubMed Web of Science ®Google Scholar
• Miller PG, Al-Shahrour F, Hartwell KA, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013 Jul 8;24(1):45–58.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Oyan AM, Kalland KH, et al. Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Prolif. 2013 Oct;46(5):554–562.
   PubMed Web of Science ®Google Scholar
• Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226–242.
   PubMed Web of Science ®Google Scholar
• Richine BM, Virts EL, Bowling JD, et al. Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia. Leukemia. 2016 Oct;30(10):2094–2097.
   PubMed Web of Science ®Google Scholar
• Sprissler C, Belenki D, Maurer H, et al. Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J. 2014 Aug 22;4:e240.
   PubMed Web of Science ®Google Scholar
• Weisberg EL, Puissant A, Stone R, et al. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 8;8(32):52026–52044.
   PubMedGoogle Scholar
• Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol. 2005 Feb;33(2):199–211.
   PubMed Web of Science ®Google Scholar
• Balaian L, Zhong RK, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol. 2003 May;31(5):363–371.
   PubMed Web of Science ®Google Scholar
• Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006 Dec;20(12):2093–2101.
   PubMed Web of Science ®Google Scholar
• Carnevale J, Ross L, Puissant A, et al. SYK regulates mTOR signaling in AML. Leukemia. 2013 Nov;27(11):2118–2128.
   PubMed Web of Science ®Google Scholar
• Long X, Yu Y, Perlaky L, et al. Stromal CYR61 confers resistance to mitoxantrone via spleen tyrosine kinase activation in human acute myeloid leukaemia. Br J Haematol. 2015 Sep;170(5):704–718.
   PubMed Web of Science ®Google Scholar
• Hwang S, Lee HJ, Kim G, et al. CCN1 acutely increases nitric oxide production via integrin alphavbeta3-Akt-S6K-phosphorylation of endothelial nitric oxide synthase at the serine 1177 signaling axis. Free Radic Biol Med. 2015 Dec;89:229–240.
   PubMed Web of Science ®Google Scholar
• Schmitz P, Gerber U, Schutze N, et al. Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4. Thromb Haemost. 2013 Nov;110(5):1046–1054.
   PubMed Web of Science ®Google Scholar
• Long QZ, Zhou M, Liu XG, et al. Interaction of CCN1 with alphavbeta3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells. Anticancer Drugs. 2013 Sep;24(8):810–817.
   PubMed Web of Science ®Google Scholar
• Jandova J, Beyer TE, Meuillet EJ, et al. The matrix protein CCN1/CYR61 is required for alpha(V)beta5-mediated cancer cell migration. Cell Biochem Funct. 2012 Dec;30(8):687–695.
   PubMed Web of Science ®Google Scholar
• Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res. 1999 Apr 10;248(1):44–57.
   PubMed Web of Science ®Google Scholar
• Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010 Jun 3;115(22):4497–4506.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Reikvam H, Bruserud O. A subset of patients with acute myeloid leukemia has leukemia cells characterized by chemokine responsiveness and altered expression of transcriptional as well as angiogenic regulators. Front Immunol. 2016;7:205.
   PubMed Web of Science ®Google Scholar
• Boros K, Puissant A, Back M, et al. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. Oncotarget. 2015 Sep 22;6(28):25575–25587.
   PubMedGoogle Scholar
• Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014 May 8;57(9):3856–3873.
   PubMed Web of Science ®Google Scholar
• Liu D, Mamorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies. J Hematol Oncol. 2017 Jul 28;10(1):145.
   PubMedGoogle Scholar
• Huang Y, Zhang Y, Fan K, et al. Discovery of new Syk inhibitors through structure-based virtual screening. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1776–1779.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008 Nov;58(11):3309–3318.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011 Feb;63(2):337–345.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Genovese MC, Ho M, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014 Dec;66(12):3255–3264.
   PubMed Web of Science ®Google Scholar
• Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016 May 19;127(20):2411–2415.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Bartlett NL, Blum KA, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016 Feb;54:11–17.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1;115(13):2578–2585.
   PubMed Web of Science ®Google Scholar
• Kaplan JB, Bixby DL, Morris JC, et al. a Phase 1b/2 study of TAK-659, an investigational dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML). Blood. 2016;128(22):2834–2835.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gordon LI, Infante JR, et al. Phase 1 dose-escalation study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with advanced solid tumor or lymphoma malignancies. Blood. 2015;126(23):2693–2694.
   Web of Science ®Google Scholar
• Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336–2343.
   PubMed Web of Science ®Google Scholar
• Walker AR, Bhatnagar B, Marcondes AMQ, et al. Interim results of a Phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with chemotherapy in patients with acute myeloid leukemia. Blood. 2016;128(22):2831–2832.
   Web of Science ®Google Scholar
• Fredly H, Ersvaer E, Kittang AO, et al. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenet. 2013 Aug 1;5(1):13.
   PubMed Web of Science ®Google Scholar
• Fredly H, Gjertsen BT, Bruserud O. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenet. 2013 Jul 30;5(1):12.
   PubMed Web of Science ®Google Scholar
• Ryningen A, Stapnes C, Lassalle P, et al. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res. 2009 Jun;33(6):779–787.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):562–569.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Di Paolo JA, Jin F, et al. Pharmacokinetics, pharmacodynamics, and safety of entospletinib, a novel pSYK inhibitor, following single and multiple oral dosing in healthy volunteers. Clin Drug Investig. 2017 Feb;37(2):195–205.
   PubMed Web of Science ®Google Scholar
• Tvedt TH, Nepstad I, Bruserud O. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Expert Opin Investig Drugs. 2017 Mar;26(3):343–355.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017 Nov 30;377(22):2167–2179.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Blazar BR, Cutler C, et al. B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jan;21(1):16–23.
   PubMed Web of Science ®Google Scholar
• Cornall RJ, Cheng AM, Pawson T, et al. Role of Syk in B-cell development and antigen-receptor signaling. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1713–1718.
   PubMed Web of Science ®Google Scholar
• Steinberg M, Adjali O, Swainson L, et al. T-cell receptor-induced phosphorylation of the zeta chain is efficiently promoted by ZAP-70 but not Syk. Blood. 2004 Aug 1;104(3):760–767.
   PubMed Web of Science ®Google Scholar
• Leonhardt F, Zirlik K, Buchner M, et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia. 2012 Jul;26(7):1617–1629.
   PubMed Web of Science ®Google Scholar
• Flynn R, Allen JL, Luznik L, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25;125(26):4085–4094.
   PubMed Web of Science ®Google Scholar
• Le Huu D, Kimura H, Date M, et al. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. J Dermatol Sci. 2014 Jun;74(3):214–221.
   PubMed Web of Science ®Google Scholar